COMMUNIQUÉS West-GlobeNewswire

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

14/08/2024 - 22:05

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and [...]

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

14/08/2024 - 22:05

Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host [...]

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

14/08/2024 - 22:05

Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 [...]

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

14/08/2024 - 22:05

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 [...]

Seer Appoints Nicolas Roelofs to its Board of Directors

14/08/2024 - 22:05

REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas [...]

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

14/08/2024 - 22:05

Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened [...]

STRATA Skin Sciences Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

14/08/2024 - 22:05

HORSHAM, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]

Windtree Announces New Additions and Changes to Its Board of Directors

14/08/2024 - 22:05

WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for [...]

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

14/08/2024 - 22:05

- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash [...]

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

14/08/2024 - 22:05

Updated clinical results from German Real-World Registry demonstrate potential for Revita ® to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment in a real-world setting Granted [...]

Actuate Therapeutics Announces Closing of Initial Public Offering

14/08/2024 - 22:05

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”) , a clinical stage biopharmaceutical company focused on developing therapies for the treatment [...]

GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

14/08/2024 - 22:05

GTB-3650 TriKE ® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in 1H 2025 GTB-5550 Phase 1 [...]

Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update

14/08/2024 - 22:05

Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B™ in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International Conference ® (AAIC) U.S [...]

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

14/08/2024 - 22:05

- Oral Fadraciclib Phase 2 Proof of Concept Study Enrolling Well - - 065-101 PoC Interim Data Anticipated in the Fourth Quarter of 2024 - - Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J [...]

Jushi Holdings Inc. Announces Option Re-Pricing Program

14/08/2024 - 22:05

BOCA RATON, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSHF ) , a vertically integrated, multi-state cannabis operator, is pleased to announce that its [...]

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

14/08/2024 - 22:05

FORTH WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug [...]

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

14/08/2024 - 22:02

- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cancers , with an [...]

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

14/08/2024 - 22:01

Generated 2Q 2024 net FUROSCIX ® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives [...]

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

14/08/2024 - 22:01

Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll [...]